Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis
Abstract Background Multiple sclerosis (MS) is a chronic and progressive neurological autoimmune disease that affects the central nervous system. There are two types of drugs used to treat this disease: injectable and oral drugs. The present study aimed at systematically reviewing the cost effective...
Saved in:
Main Authors: | Mehdi Rezaee, Ramin Ravangard, Seyyed Morteza Mojtabaeian, Abdosaleh Jafari |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-10-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12913-024-11800-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Cost-effectiveness of oral versus injectable disease modifying therapies in relapsing multiple sclerosis: a systematic review analysis
by: Mehdi Rezaee, et al.
Published: (2025-01-01) -
First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Rong Long, et al.
Published: (2024-12-01) -
Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis
by: Saeed Vaheb, et al.
Published: (2025-01-01) -
Matters arising: cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
by: Carlo Lazzaro, et al.
Published: (2025-01-01) -
Treatment with perilesional injections of pentoxifylline in patients with Peyronie's disease improves the therapeutic effect of oral and topical antioxidant therapy
by: Gianni Paulis, et al.
Published: (2025-02-01)